Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
about
Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosisImproving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cellsA New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-GuérenHeat shock proteins: novel therapeutic tools for HIV-infection?Recombinant BCG as a vaccine vehicle to protect against tuberculosis.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesTh1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.Immunomodulatory agents in the laboratory and clinic.Contributions of laboratory research to current understanding and management of leprosy.Mycobacterial protein antigens: a compilation.Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlRecombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.Probiotics: multifarious oral vaccine against infectious traumas.MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.Cellular and humoral immune responses to recombinant antigens in sheep infected with Toxoplasma gondii.Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.Vaccine strategies: targeting helper T cell responses.Vaccination against tuberculosis: is BCG more sinned against than sinner?HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions.Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery.Development of vaccine strategies for the treatment of B-cell malignancies.Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses.Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model.Is an AIDS vaccine possible?Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants.
P2860
Q28243702-10DF5FD3-A73E-4CD4-AAB4-6EFE6D33E1FDQ28543248-4C228F3E-67DE-4D9E-BFF4-F581229B9DCEQ28551001-A4E3015A-819B-46B5-B684-332CFAC5BF20Q34452131-3D0D26B5-E754-4EC9-B5CD-A3F7188460D8Q34518560-978ADFE9-A962-4767-95F6-BEB65F831309Q34983688-588C6ADF-C011-40C0-86A2-938B64E7999DQ35215350-F314A64B-89ED-4870-A4C6-C2A70F3A4F9EQ35224457-271B7A37-6BC7-49A0-80DD-7D1CA2CF7F64Q35664241-F875CE48-A476-4E7C-B587-DFA18E0A62ACQ35905103-549EBDF4-5D4A-4033-80F3-EC1AED4DF734Q35909944-AECB8945-D0E0-403E-9B09-C104DC8B0863Q36404193-53843794-17CF-43D7-BB2E-0FAE316CC134Q36690291-30F6BDF6-F726-4BE9-9077-63C3C2A2C039Q37681016-89304363-DAF3-433F-964E-827B8FEAF8FAQ37737313-126375A9-A687-4982-83A6-0E7D18CEE68EQ38954576-26407BC9-BBCE-4224-A543-248C98D241D4Q40234787-8A09F43F-1442-4FBD-9029-B58C1D48A3FFQ40454293-14FE3EE6-E3DF-45EA-AA01-E3C006D407DDQ40795558-347CE06B-C633-4CCF-B3AB-E6D100B0AC63Q40927003-0BF9EFF2-0F3C-45A5-AD7F-4DC14065DB45Q40985243-E6486CEF-9A3C-4687-BC36-07C9DDCBADB2Q41669410-F900AD19-8DE7-4F44-98EB-9E5B41589803Q42165676-3627E565-BEB4-453E-AC43-5F85B3E96FFDQ42600866-F764EA9E-7EA2-4D59-9524-9A11F5099BF6Q43731754-F380997E-BFEB-4A3B-B18E-9B995A22A7A0Q43881637-86DBE92E-1C72-4365-B4A8-FB40F6E55DB5Q45885655-2AEEE09B-F54F-45D6-953C-998F79D78161Q48022785-8C4DC4F3-7B01-45E8-9E48-58992467E6DA
P2860
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
description
article publié dans la revue scientifique Nature
@fr
scientific article published in Nature
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в Nature в червні 1991
@uk
name
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@en
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@nl
type
label
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@en
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@nl
prefLabel
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@en
Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines
@nl
P356
P1433
P1476
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
@en
P2093
P2888
P304
P356
10.1038/351479A0
P407
P577
1991-06-01T00:00:00Z
P6179
1037478855